Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.24
ANTM's Cash-to-Debt is ranked lower than
82% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.15 vs. ANTM: 0.24 )
Ranked among companies with meaningful Cash-to-Debt only.
ANTM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.09  Med: 0.25 Max: 0.59
Current: 0.24
0.09
0.59
Equity-to-Asset 0.39
ANTM's Equity-to-Asset is ranked higher than
52% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.38 vs. ANTM: 0.39 )
Ranked among companies with meaningful Equity-to-Asset only.
ANTM' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.44 Max: 0.51
Current: 0.39
0.33
0.51
Debt-to-Equity 0.67
ANTM's Debt-to-Equity is ranked lower than
74% of the 19 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.59 vs. ANTM: 0.67 )
Ranked among companies with meaningful Debt-to-Equity only.
ANTM' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.18  Med: 0.41 Max: 0.75
Current: 0.67
0.18
0.75
Debt-to-EBITDA 3.10
ANTM's Debt-to-EBITDA is ranked lower than
83% of the 18 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.82 vs. ANTM: 3.10 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ANTM' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1  Med: 2.55 Max: 3.56
Current: 3.1
1
3.56
Beneish M-Score: -2.69
WACC vs ROIC
7.87%
24.61%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Net Margin % 4.79
ANTM's Net Margin % is ranked higher than
56% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 3.87 vs. ANTM: 4.79 )
Ranked among companies with meaningful Net Margin % only.
ANTM' s Net Margin % Range Over the Past 10 Years
Min: 2.91  Med: 4.17 Max: 7.3
Current: 4.79
2.91
7.3
ROE % 16.13
ANTM's ROE % is ranked lower than
58% of the 26 Companies
in the Global Health Care Plans industry.

( Industry Median: 15.89 vs. ANTM: 16.13 )
Ranked among companies with meaningful ROE % only.
ANTM' s ROE % Range Over the Past 10 Years
Min: 10.25  Med: 11.23 Max: 20.5
Current: 16.13
10.25
20.5
ROA % 6.12
ANTM's ROA % is ranked higher than
57% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 4.25 vs. ANTM: 6.12 )
Ranked among companies with meaningful ROA % only.
ANTM' s ROA % Range Over the Past 10 Years
Min: 3.9  Med: 4.87 Max: 9.44
Current: 6.12
3.9
9.44
3-Year Revenue Growth Rate 9.20
ANTM's 3-Year Revenue Growth Rate is ranked higher than
65% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 8.60 vs. ANTM: 9.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ANTM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -11.1  Med: 11.8 Max: 18.3
Current: 9.2
-11.1
18.3
3-Year EBITDA Growth Rate 0.90
ANTM's 3-Year EBITDA Growth Rate is ranked lower than
80% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 12.70 vs. ANTM: 0.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ANTM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 10.9 Max: 93.3
Current: 0.9
0
93.3
3-Year EPS without NRI Growth Rate 17.00
ANTM's 3-Year EPS without NRI Growth Rate is ranked lower than
56% of the 16 Companies
in the Global Health Care Plans industry.

( Industry Median: 17.70 vs. ANTM: 17.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ANTM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 7.7 Max: 27
Current: 17
0
27
GuruFocus has detected 4 Warning Signs with Anthem Inc ANTM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ANTM's 30-Y Financials

Financials (Next Earnings Date: 2018-10-25)


Revenue & Net Income
Equity & Asset
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

ANTM Guru Trades in Q3 2017

Ray Dalio 6,199 sh (New)
Julian Robertson 103,000 sh (New)
Caxton Associates 3,100 sh (New)
Andreas Halvorsen 873,464 sh (+204.68%)
Lee Ainslie 18,640 sh (+45.28%)
Jim Simons 1,169,973 sh (+34.91%)
Joel Greenblatt 37,813 sh (+3.58%)
First Eagle Investment 3,103,892 sh (+2.35%)
HOTCHKIS & WILEY 2,393,810 sh (+0.54%)
Yacktman Fund 850,000 sh (unchged)
Tom Gayner 224,000 sh (unchged)
Bernard Horn 36,600 sh (unchged)
Daniel Loeb 1,250,000 sh (unchged)
David Dreman 5,949 sh (unchged)
Yacktman Asset Management 1,022,503 sh (-0.58%)
Jeff Auxier 50,319 sh (-3.45%)
Vanguard Health Care Fund 2,391,733 sh (-4.42%)
Larry Robbins 3,802,515 sh (-6.13%)
Jeremy Grantham 1,022,758 sh (-6.65%)
T Rowe Price Equity Income Fund 1,830,000 sh (-9.74%)
Paul Tudor Jones 11,137 sh (-10.17%)
First Pacific Advisors 11,050 sh (-13.33%)
Alan Fournier 193,800 sh (-14.25%)
NWQ Managers 6,400 sh (-20.00%)
Pioneer Investments 17,893 sh (-34.41%)
Signature Select Canadian Fund 34,500 sh (-47.96%)
Barrow, Hanley, Mewhinney & Strauss 2,580,638 sh (-61.17%)
Dodge & Cox 2,200 sh (-96.68%)
» More
Q4 2017

ANTM Guru Trades in Q4 2017

Steven Cohen 162,700 sh (New)
Tom Russo 100 sh (New)
Eaton Vance Worldwide Health Sciences Fund 51,042 sh (New)
Pioneer Investments 219,061 sh (+1124.28%)
Andreas Halvorsen 2,537,576 sh (+190.52%)
Lee Ainslie 29,200 sh (+56.65%)
Paul Tudor Jones 11,904 sh (+6.89%)
First Eagle Investment 3,143,500 sh (+1.28%)
Tom Gayner 224,000 sh (unchged)
David Dreman 5,949 sh (unchged)
Dodge & Cox 2,200 sh (unchged)
Bernard Horn 36,600 sh (unchged)
Ray Dalio Sold Out
Caxton Associates Sold Out
NWQ Managers Sold Out
Jeff Auxier 49,694 sh (-1.24%)
T Rowe Price Equity Income Fund 1,800,000 sh (-1.64%)
Joel Greenblatt 36,283 sh (-4.05%)
Barrow, Hanley, Mewhinney & Strauss 2,475,627 sh (-4.07%)
Julian Robertson 97,500 sh (-5.34%)
Alan Fournier 183,379 sh (-5.38%)
Jeremy Grantham 956,507 sh (-6.48%)
Vanguard Health Care Fund 2,104,933 sh (-11.99%)
Yacktman Fund 700,000 sh (-17.65%)
Yacktman Asset Management 835,712 sh (-18.27%)
Larry Robbins 3,057,497 sh (-19.59%)
First Pacific Advisors 7,350 sh (-33.48%)
HOTCHKIS & WILEY 1,466,718 sh (-38.73%)
Jim Simons 671,600 sh (-42.60%)
Daniel Loeb 375,000 sh (-70.00%)
» More
Q1 2018

ANTM Guru Trades in Q1 2018

Jana Partners 610,593 sh (New)
Ray Dalio 7,493 sh (New)
Caxton Associates 1,901 sh (New)
Daniel Loeb 785,000 sh (+109.33%)
Andreas Halvorsen 4,429,548 sh (+74.56%)
Lee Ainslie 39,430 sh (+35.03%)
Jeremy Grantham 1,263,383 sh (+32.08%)
Pioneer Investments 254,723 sh (+16.28%)
Jeff Auxier 50,159 sh (+0.94%)
Eaton Vance Worldwide Health Sciences Fund 85,211 sh (+66.94%)
Yacktman Fund 700,000 sh (unchged)
Tom Gayner 224,000 sh (unchged)
David Dreman 5,949 sh (unchged)
First Pacific Advisors 7,350 sh (unchged)
Bernard Horn 36,600 sh (unchged)
Tom Russo Sold Out
Paul Tudor Jones Sold Out
Alan Fournier Sold Out
Yacktman Asset Management 826,673 sh (-1.08%)
Barrow, Hanley, Mewhinney & Strauss 2,422,372 sh (-2.15%)
Jim Simons 633,273 sh (-5.71%)
First Eagle Investment 2,948,535 sh (-6.20%)
Vanguard Health Care Fund 1,973,833 sh (-6.23%)
T Rowe Price Equity Income Fund 1,650,000 sh (-8.33%)
HOTCHKIS & WILEY 1,331,801 sh (-9.20%)
Steven Cohen 135,100 sh (-16.96%)
Larry Robbins 2,281,335 sh (-25.39%)
Dodge & Cox 1,400 sh (-36.36%)
Signature Select Canadian Fund 15,900 sh (-53.91%)
Julian Robertson 44,500 sh (-54.36%)
Joel Greenblatt 4,663 sh (-87.15%)
» More
Q2 2018

ANTM Guru Trades in Q2 2018

Murray Stahl 846 sh (New)
Joel Greenblatt 17,548 sh (+276.32%)
Steven Cohen 301,653 sh (+123.28%)
First Eagle Investment 3,041,254 sh (+3.14%)
Pioneer Investments 260,629 sh (+2.32%)
Barrow, Hanley, Mewhinney & Strauss 2,441,866 sh (+0.80%)
Andreas Halvorsen 4,454,770 sh (+0.57%)
Eaton Vance Worldwide Health Sciences Fund 85,985 sh (+0.91%)
Yacktman Fund 700,000 sh (unchged)
Vanguard Health Care Fund 1,973,833 sh (unchged)
Tom Gayner 224,000 sh (unchged)
First Pacific Advisors 7,350 sh (unchged)
Dodge & Cox 1,400 sh (unchged)
Daniel Loeb Sold Out
Julian Robertson Sold Out
Ray Dalio Sold Out
Caxton Associates Sold Out
Yacktman Asset Management 821,056 sh (-0.68%)
Jeff Auxier 49,746 sh (-0.82%)
HOTCHKIS & WILEY 1,304,876 sh (-2.02%)
T Rowe Price Equity Income Fund 1,585,000 sh (-3.94%)
Jana Partners 539,868 sh (-11.58%)
Jeremy Grantham 1,113,060 sh (-11.90%)
Lee Ainslie 33,050 sh (-16.18%)
Bernard Horn 29,200 sh (-20.22%)
Larry Robbins 1,275,662 sh (-44.08%)
Jim Simons 120,673 sh (-80.94%)
» More
» Details

Insider Trades

Latest Guru Trades with ANTM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
First Eagle Investment 2018-06-30 Add 3.14%0.05%$220.13 - $245.16 $ 278.4220%3,041,254
Barrow, Hanley, Mewhinney & Strauss 2018-06-30 Add 0.80%0.01%$220.13 - $245.16 $ 278.4220%2,441,866
T Rowe Price Equity Income Fund 2018-06-30 Reduce -3.94%0.07%$220.13 - $245.16 $ 278.4220%1,585,000
HOTCHKIS & WILEY 2018-06-30 Reduce -2.02%0.02%$220.13 - $245.16 $ 278.4220%1,304,876
Yacktman Asset Management 2018-06-30 Reduce -0.68%0.01%$220.13 - $245.16 $ 278.4220%821,056
Joel Greenblatt 2018-06-30 Add 276.32%0.04%$220.13 - $245.16 $ 278.4220%17,548
Julian Robertson 2018-06-30 Sold Out 1.25%$220.13 - $245.16 $ 278.4220%0
First Eagle Investment 2018-03-31 Reduce -6.20%0.1%$215.63 - $258.19 $ 278.4219%2,948,535
Barrow, Hanley, Mewhinney & Strauss 2018-03-31 Reduce -2.15%0.02%$215.63 - $258.19 $ 278.4219%2,422,372
Vanguard Health Care Fund 2018-03-31 Reduce -6.23%0.06%$215.63 - $258.19 $ 278.4219%1,973,833
T Rowe Price Equity Income Fund 2018-03-31 Reduce -8.33%0.16%$215.63 - $258.19 $ 278.4219%1,650,000
HOTCHKIS & WILEY 2018-03-31 Reduce -9.20%0.11%$215.63 - $258.19 $ 278.4219%1,331,801
Yacktman Asset Management 2018-03-31 Reduce -1.08%0.02%$215.63 - $258.19 $ 278.4219%826,673
Julian Robertson 2018-03-31 Reduce -54.36%1.86%$215.63 - $258.19 $ 278.4219%44,500
Joel Greenblatt 2018-03-31 Reduce -87.15%0.1%$215.63 - $258.19 $ 278.4219%4,663
Dodge & Cox 2018-03-31 Reduce -36.36%$215.63 - $258.19 $ 278.4219%1,400
First Eagle Investment 2017-12-31 Add 1.28%0.02%$183.76 - $232.34 $ 278.4231%3,143,500
Barrow, Hanley, Mewhinney & Strauss 2017-12-31 Reduce -4.07%0.03%$183.76 - $232.34 $ 278.4231%2,475,627
Vanguard Health Care Fund 2017-12-31 Reduce -11.99%0.12%$183.76 - $232.34 $ 278.4231%2,104,933
T Rowe Price Equity Income Fund 2017-12-31 Reduce -1.64%0.03%$183.76 - $232.34 $ 278.4231%1,800,000
HOTCHKIS & WILEY 2017-12-31 Reduce -38.73%0.69%$183.76 - $232.34 $ 278.4231%1,466,718
Yacktman Asset Management 2017-12-31 Reduce -18.27%0.34%$183.76 - $232.34 $ 278.4231%835,712
Yacktman Fund 2017-12-31 Reduce -17.65%0.45%$183.76 - $232.34 $ 278.4231%700,000
Julian Robertson 2017-12-31 Reduce -5.34%0.19%$183.76 - $232.34 $ 278.4231%97,500
Joel Greenblatt 2017-12-31 Reduce -4.05%$183.76 - $232.34 $ 278.4231%36,283
NWQ Managers 2017-12-31 Sold Out 0.02%$183.76 - $232.34 $ 278.4231%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Plans » Health Care Plans    NAICS: 524114    SIC: 6324
Compare:NYSE:AET, NYSE:CVS, NAS:ESRX, NYSE:CI, NYSE:HUM, NYSE:CNC, NYSE:WCG, NYSE:MOH, BSP:ODPV3, BSP:QUAL3, NAS:MGLN, XPAR:GDS, NAS:HIIQ, OSTO:MCOV B, ROCO:6665, ATH:IATR, ASX:ONT, TSXV:NAC, MIL:HI, OTCPK:HFRN » details
Traded in other countries:A58.Germany, ANTM.Mexico,
Headquarter Location:USA
Anthem Inc is a health benefits company offering a network-based managed care plans to the large and small employer, individual, Medicaid and Medicare markets. Its business segments are Commercial and Specialty Business, Government Business and Other.

With over 40 million medical members, Anthem is one of the largest managed-care organizations in the United States. The firm provides health insurance services to its members through a plethora of products that encompass every major insurance market--individual, group, and government-sponsored. The firm operates under the highly recognizable Blue Cross/Blue Shield brand in 14 states and has a large nationwide operation.

Guru Investment Theses on Anthem Inc

Jeff Auxier Comments on Anthem Inc. - Aug 08, 2018

Anthem Inc. (NYSE:ANTM)



Total operating revenues in the most recent quarter remained flat at $22.3 billion. The total operating margin increased by 130 basis points to 8.4%. Net income for the quarter increased by 30% to $1.31 billion. The increase in net income was driven by improved cost management and a lower tax rate. Anthem paid dividends of $0.75 per share in both Q1 and Q2 which equates to an annual dividend of $3.00 per share.



From Jeff Auxier (Trades, Portfolio)'s second quarter 2018 shareholder letter.

Check out Jeff Auxier latest stock trades

Leith Wheeler Comments on Anthem - Mar 09, 2018

Lastly, managed care business Anthem, Inc. (NYSE:ANTM) (+19.5%) performed well during the quarter and the year, adding to relative performance over both periods. Improving pricing, cost, and utilization trends, along with tailwinds from corporate tax reform and political relief from the reduced impact of the Affordable Care Act, all contributed to the stock’s outperformance. Anthem trades at a compelling valuation and offers significant upside to our target price.



From Leith Wheeler Investment Funds' 4th quarter 2017 commentary.



Check out Leith Wheeler Canadian Equity latest stock trades

Jeff Auxier Comments on Anthem - Feb 06, 2018

Anthem (NYSE:ANTM)’s three reportable segments all had operating revenue growth in the most recent quarter while cutting total expenses by 5%. After ongoing accusations of Express Scripts overcharging by billions of dollars, Anthem announced its plan to set up its own pharmacy benefits management unit called IngenioRx and secured a five-year agreement with CVS Health Corp. that will go into effect at the end of 2019.











From Jeff Auxier (Trades, Portfolio)'s fourth quarter 2018 shareholder letter.

Check out Jeff Auxier latest stock trades

Jeff Auxier Comments on Anthem - May 09, 2017

Anthem (NYSE:ANTM) is a leading managed care operator which operates under the Blue Cross/Blue Shield brand. Fourth quarter net income was up 103% year over year as medical enrollment increased 3.4%. They are expecting their operating cash flow to be greater than $3.5B in 2017.


From Jeff Auxier (Trades, Portfolio)'s Auxier Asset Management first quarter 2017 shareholder letter.

Check out Jeff Auxier latest stock trades

Bernard Horn Comments on Anthem - Apr 21, 2017

From the outset, investors and analysts raised concerns about the proposed merger between U.S. health insurers, Anthem, Inc. and Cigna. In early January 2017, a federal judge blocked the proposed merger, siding with the Department of Justice. Anthem (NYSE:ANTM) stock rose in the ensuing three months, up more than 15% at the end of March, as investors were relieved about the deal cancellation. In February, the Centers for Medicare & Medicaid Services proposed rules aimed at stabilizing the Affordable Care Act (ACA) individual and small group insurance markets. This bodes well for Anthem Inc., and other health insurers, as the rule may help stem the tide of financial losses currently associated with ACA participation.

From Bernard Horn (Trades, Portfolio)'s Polaris Global Fund first quarter 2017 shareholder letter.

Check out Bernard Horn latest stock trades

Top Ranked Articles about Anthem Inc

Actinium Pharmaceuticals to Host Webinar Showcasing New Pipeline Initiative Focused on the CAR-T Space
Jeff Auxier Comments on Anthem Inc. Guru stock highlight
Anthem Inc. (NYSE:ANTM)
Read more...
Diplomat Pharmacy Appoints Brian Griffin as Chief Executive Officer and Chairman of the Board
5 Companies Hit 52-Week Highs As of late, multiple companies have all managed to achieve yearly peaks
According to GuruFocus list of 52-week highs, these Guru stocks have reached their 52-Week Highs. Read more...
Five Companies Reach 52-Week Highs As of late, multiple companies have all managed to achieve yearly highs
According to GuruFocus list of 52-week highs, these Guru stocks have reached their 52-Week Highs. Read more...
Scott+Scott Attorneys at Law LLP is Investigating Derivative Claims on Behalf of Shareholders of Anthem, Inc. (ANTM)
Leith Wheeler Comments on Anthem Guru stock highlight
Lastly, managed care business Anthem, Inc. (NYSE:ANTM) (+19.5%) performed well during the quarter and the year, adding to relative performance over both periods. Improving pricing, cost, and utilization trends, along with tailwinds from corporate tax reform and political relief from the reduced impact of the Affordable Care Act, all contributed to the stock’s outperformance. Anthem trades at a compelling valuation and offers significant upside to our target price. Read more...
Jeff Auxier Comments on Anthem Guru stock highlight
Anthem (NYSE:ANTM)’s three reportable segments all had operating revenue growth in the most recent quarter while cutting total expenses by 5%. After ongoing accusations of Express Scripts overcharging by billions of dollars, Anthem announced its plan to set up its own pharmacy benefits management unit called IngenioRx and secured a five-year agreement with CVS Health Corp. that will go into effect at the end of 2019.
Read more...
Anthem Soars on Strong Operating Revenue Growth Company reports solid performance in 2017 and raises outlook for 2018
Anthem Inc. (NYSE:ANTM), a major health benefits company, said fourth-quarter operating revenues increased 4.5% year over year, capping a strong finish to fiscal 2017. Read more...
Eaton Vance Worldwide Health Sciences Fund Starts 3 Positions in 4th Quarter Fund reports quarterly portfolio
The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) primarily invests in companies engaged in the discovery, development, production or distribution of products and services related to scientific advances in health care. Read more...

Ratios

vs
industry
vs
history
PE Ratio 16.95
ANTM's PE Ratio is ranked higher than
67% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 19.79 vs. ANTM: 16.95 )
Ranked among companies with meaningful PE Ratio only.
ANTM' s PE Ratio Range Over the Past 10 Years
Min: 4.33  Med: 10.51 Max: 19.97
Current: 16.95
4.33
19.97
Forward PE Ratio 15.77
ANTM's Forward PE Ratio is ranked lower than
54% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 14.27 vs. ANTM: 15.77 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 16.95
ANTM's PE Ratio without NRI is ranked higher than
67% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 19.79 vs. ANTM: 16.95 )
Ranked among companies with meaningful PE Ratio without NRI only.
ANTM' s PE Ratio without NRI Range Over the Past 10 Years
Min: 4.33  Med: 10.36 Max: 19.97
Current: 16.95
4.33
19.97
Price-to-Owner-Earnings 26.81
ANTM's Price-to-Owner-Earnings is ranked lower than
56% of the 16 Companies
in the Global Health Care Plans industry.

( Industry Median: 16.47 vs. ANTM: 26.81 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ANTM' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.16  Med: 11.84 Max: 35.03
Current: 26.81
4.16
35.03
PB Ratio 2.52
ANTM's PB Ratio is ranked higher than
81% of the 26 Companies
in the Global Health Care Plans industry.

( Industry Median: 3.42 vs. ANTM: 2.52 )
Ranked among companies with meaningful PB Ratio only.
ANTM' s PB Ratio Range Over the Past 10 Years
Min: 0.71  Med: 1.16 Max: 2.52
Current: 2.52
0.71
2.52
PS Ratio 0.82
ANTM's PS Ratio is ranked higher than
56% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.73 vs. ANTM: 0.82 )
Ranked among companies with meaningful PS Ratio only.
ANTM' s PS Ratio Range Over the Past 10 Years
Min: 0.26  Med: 0.44 Max: 0.88
Current: 0.82
0.26
0.88
Price-to-Free-Cash-Flow 26.20
ANTM's Price-to-Free-Cash-Flow is ranked lower than
61% of the 18 Companies
in the Global Health Care Plans industry.

( Industry Median: 12.78 vs. ANTM: 26.20 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ANTM' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.81  Med: 11.49 Max: 50.53
Current: 26.2
5.81
50.53
Price-to-Operating-Cash-Flow 19.16
ANTM's Price-to-Operating-Cash-Flow is ranked lower than
65% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 12.15 vs. ANTM: 19.16 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ANTM' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.17  Med: 9.7 Max: 26.92
Current: 19.16
5.17
26.92
EV-to-EBIT 12.92
ANTM's EV-to-EBIT is ranked higher than
71% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 13.89 vs. ANTM: 12.92 )
Ranked among companies with meaningful EV-to-EBIT only.
ANTM' s EV-to-EBIT Range Over the Past 10 Years
Min: 1.5  Med: 5.8 Max: 13.4
Current: 12.92
1.5
13.4
EV-to-EBITDA 10.85
ANTM's EV-to-EBITDA is ranked higher than
52% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 9.81 vs. ANTM: 10.85 )
Ranked among companies with meaningful EV-to-EBITDA only.
ANTM' s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.4  Med: 5 Max: 11.3
Current: 10.85
1.4
11.3
EV-to-Revenue 0.75
ANTM's EV-to-Revenue is ranked higher than
59% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.01 vs. ANTM: 0.75 )
Ranked among companies with meaningful EV-to-Revenue only.
ANTM' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.1  Med: 0.4 Max: 0.9
Current: 0.75
0.1
0.9
PEG Ratio 2.36
ANTM's PEG Ratio is ranked lower than
77% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.35 vs. ANTM: 2.36 )
Ranked among companies with meaningful PEG Ratio only.
ANTM' s PEG Ratio Range Over the Past 10 Years
Min: 0.24  Med: 0.88 Max: 8.93
Current: 2.36
0.24
8.93
Shiller PE Ratio 27.54
ANTM's Shiller PE Ratio is ranked higher than
69% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 27.53 vs. ANTM: 27.54 )
Ranked among companies with meaningful Shiller PE Ratio only.
ANTM' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.07  Med: 15.72 Max: 27.73
Current: 27.54
9.07
27.73

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.05
ANTM's Dividend Yield % is ranked lower than
52% of the 31 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.02 vs. ANTM: 1.05 )
Ranked among companies with meaningful Dividend Yield % only.
ANTM' s Dividend Yield % Range Over the Past 10 Years
Min: 0.31  Med: 1.52 Max: 2.16
Current: 1.05
0.31
2.16
Dividend Payout Ratio 0.18
ANTM's Dividend Payout Ratio is ranked higher than
73% of the 15 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.27 vs. ANTM: 0.18 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ANTM' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.14  Med: 0.19 Max: 0.28
Current: 0.18
0.14
0.28
3-Year Dividend Growth Rate 15.60
ANTM's 3-Year Dividend Growth Rate is ranked lower than
63% of the 8 Companies
in the Global Health Care Plans industry.

( Industry Median: 19.40 vs. ANTM: 15.60 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
ANTM' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 29.5
Current: 15.6
0
29.5
Forward Dividend Yield % 1.12
ANTM's Forward Dividend Yield % is ranked lower than
71% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.33 vs. ANTM: 1.12 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 2.57
ANTM's 5-Year Yield-on-Cost % is ranked lower than
61% of the 38 Companies
in the Global Health Care Plans industry.

( Industry Median: 4.89 vs. ANTM: 2.57 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ANTM' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.76  Med: 3.72 Max: 5.29
Current: 2.57
0.76
5.29
3-Year Average Share Buyback Ratio 1.50
ANTM's 3-Year Average Share Buyback Ratio is ranked higher than
65% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: -0.50 vs. ANTM: 1.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ANTM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -43.1  Med: 3.6 Max: 12.2
Current: 1.5
-43.1
12.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.22
ANTM's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
53% of the 15 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.08 vs. ANTM: 1.22 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ANTM' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.32  Med: 0.55 Max: 1.47
Current: 1.22
0.32
1.47
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.35
ANTM's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
67% of the 9 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.02 vs. ANTM: 1.35 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
ANTM' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.33  Med: 0.91 Max: 1.49
Current: 1.35
0.33
1.49
Price-to-Median-PS-Value 1.85
ANTM's Price-to-Median-PS-Value is ranked lower than
65% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.19 vs. ANTM: 1.85 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ANTM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.72  Med: 1.16 Max: 2.54
Current: 1.85
0.72
2.54
Price-to-Peter-Lynch-Fair-Value 2.83
ANTM's Price-to-Peter-Lynch-Fair-Value is ranked lower than
82% of the 11 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.09 vs. ANTM: 2.83 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ANTM' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.29  Med: 0.67 Max: 3.13
Current: 2.83
0.29
3.13
Earnings Yield (Greenblatt) % 7.73
ANTM's Earnings Yield (Greenblatt) % is ranked higher than
79% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 6.22 vs. ANTM: 7.73 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ANTM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 7.4  Med: 17.4 Max: 67.2
Current: 7.73
7.4
67.2
Forward Rate of Return (Yacktman) % 10.15
ANTM's Forward Rate of Return (Yacktman) % is ranked lower than
69% of the 16 Companies
in the Global Health Care Plans industry.

( Industry Median: 16.01 vs. ANTM: 10.15 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ANTM' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 6.2  Med: 19.7 Max: 37
Current: 10.15
6.2
37

More Statistics

Revenue (TTM) (Mil) $90,587.50
EPS (TTM) $ 16.42
Beta0.99
Volatility24.01%
52-Week Range $182.71 - 280.43
Shares Outstanding (Mil)259.95

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 91,656 95,690 102,144
EBIT (Mil $) 5,005 5,917 5,799
EBITDA (Mil $) 5,916 6,144 6,220
EPS ($) 14.30 15.69 17.52
EPS without NRI ($) 14.30 15.69 17.52
EPS Growth Rate
(Future 3Y To 5Y Estimate)
4.66%
Dividends per Share ($) 2.84 2.87 3.00

Piotroski F-Score Details

Piotroski F-Score: ----
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}